284P Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Asian Patients ◽

329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.08.612 ◽

2021 ◽

Vol 32 ◽

pp. S509

Author(s):

S. Loi ◽

A. Schneeweiss ◽

E. Song ◽

M. Harries ◽

M. De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase Iii Study ◽

PCN104 Cost-Utility MODEL of Trastuzumab Emtansine (T-DM1) in HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab and a Taxane, Compared with Capecitabine PLUS Lapatinib, Trastuzumab PLUS Capecitabine and Capecitabine ALONE in Turkey

Value in Health ◽

10.1016/j.jval.2020.08.241 ◽

2020 ◽

Vol 23 ◽

pp. S441

Author(s):

B. Akyol Ersoy ◽

E. Erdogan-Ciftci ◽

L. Yanik ◽

B. Guler ◽

G. Ozcan ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Cost Utility ◽

Trastuzumab Emtansine ◽

Utility Model ◽

Her2 Positive ◽

EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps116 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS116-TPS116 ◽

Cited By ~ 2

Author(s):

S. Verma ◽

V. Dieras ◽

L. Gianni ◽

D. Miles ◽

M. Welslau ◽

...

Keyword(s):

Breast Cancer ◽

Multicenter Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Abstract OT-28-03: VICKI: A Phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs20-ot-28-03 ◽

2021 ◽

Author(s):

Geoffrey J Lindeman ◽

Erika Hamilton ◽

Ian Krop ◽

Bora Lim ◽

Shanu Modi ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Controlled Study ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase Ib ◽

A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04298918 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Safety And Efficacy ◽

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyy097 ◽

2018 ◽

Vol 48 (9) ◽

pp. 855-859 ◽

Cited By ~ 2

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Takayuki Ueno ◽

Naruto Taira ◽

Masahiro Kashiwaba ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

ADCs Approved for Use: Trastuzumab Emtansine (Kadcyla®, T-DM1) in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

Antibody-Drug Conjugates ◽

10.1002/9781119060727.ch14 ◽

2016 ◽

pp. 345-380 ◽

Cited By ~ 1

Author(s):

Gail D. Lewis Phillips ◽

Sanne de Haas ◽

Sandhya Girish ◽

Ellie Guardino

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Abstract P3-14-22: Pharmacokinetics (PK) of Trastuzumab-DM1 (T-DM1) and Paclitaxel (T) in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen

10.1158/0008-5472.sabcs10-p3-14-22 ◽

2010 ◽

Cited By ~ 4

Author(s):

D Lu ◽

I Krop ◽

S Modi ◽

A Elias ◽

P LoRusso ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Her2 Positive ◽

Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

10.1158/0008-5472.sabcs12-s6-6 ◽

2012 ◽

Cited By ~ 24

Author(s):

PA Kaufman ◽

A Awada ◽

C Twelves ◽

L Yelle ◽

EA Perez ◽

...

Keyword(s):

Breast Cancer ◽

Multicenter Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Open Label ◽

Eribulin Mesylate ◽

Abstract OT3-01-01: HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)

10.1158/1538-7445.sabcs15-ot3-01-01 ◽

2016 ◽

Author(s):

K Miller ◽

J Cortes ◽

SA Hurvitz ◽

IE Krop ◽

D Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

Open Label Trial